The diagnostic value of fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has not been thoroughly evaluated in patients with leukemia. We herein report the case of a patient with B cell acute lymphoblastic leukemia (ALL) presenting with fever of unknown origin (FUO) who was diagnosed after FDG PET/CT indicated diffuse bone marrow involvement.
Introduction
Diseases that cause fever of unknown origin (FUO) range from infections to malignancies and autoimmune diseases (1) . In recent years, fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has been used as the last resort diagnostic modality in FUO patients, with great success, where conventional methods have failed (2, 3) . Both anatomic and metabolic information has proved to have significant benefits in the diagnostic workup of FUO. We herein report the case of a patient with B cell acute lymphoblastic leukemia (ALL) presenting with FUO who was diagnosed after FDG PET/CT showed diffuse bone marrow involvement.
Case Report
A 51-year-old man was referred to our hospital due to a high fever and asthenia for the previous four months. The findings of a physical examination were normal, except for hepatomegaly. A hemogram showed a white blood cell count of 5,480/mm 3 (neutrophils, 37.6%; basophils, 3.4%; monocytes, 24.7%; lymphocytes, 34,3%), a hemoglobin level of 10.7 g/dL and a platelet count of 238,000/mm 3 . Routine biochemistry tests were normal, except for the erythrocyte sedimentation rate (101; normal range <20/hour) and levels of serum ferritin (1,827; normal range 30-400), triglycerides (232; normal range <150 mg/dL), lactate dehydrogenase (1,091 IU/L; normal range, 135 to 225 IU/L) and C-reactive protein (69.46 mg/L; normal range, <5 mg/L). Contrast-enhanced thorax and abdominal computed tomography revealed no evidence of abnormalities, except for hepatomegaly (190 mm). FDG PET/CT performed to rule out any possible malignant neoplasms showed a diffuse high FDG uptake in the bone marrow ( Figure) . A bone marrow biopsy revealed 30% lymphoblasts, and the results of a flow cytometric immunophenotypic analysis were compatible with the findings of precursor B cell lymphoblastic leukemia. A flow cytometric immunophenotyping analysis showed that approximately 44% leukemic cells expressed CD19, CD20, CD22, CD10 and CD34 Tdt+ antigens, compatible with a diagnosis of precursor B cell lymphoblastic leukemia. breakpoint cluster region (BCR)/ABL was negative using the polymerase chain reaction (PCR) method. No abnormalities were found in the bone marrow karyotype analysis. 
Discussion
PET/CT is a very important tool in the diagnosis and staging of hematological malignancies, particularly lymphomas. Case reports showing the diagnostic value of PET/CT in various forms of leukemia, including intramedullary and extramedullary relapse of acute myeloid leukemia, myeloid sarcoma, plasma cell leukemia and NK-cell leukemia, have been reported (4-9).
We found two cases of ALL diagnosed incidentally on PET/CT scanning during our search of the medical literature (10, 11). Ennishi et al. reported a patient referred to their hospital with a long-term fever and diffuse bone pain. Routine hematologic and radiologic (CT and MRI techniques) investigations did not reveal any abnormalities. FDG PET/CT showed a diffuse and increased bone marrow uptake, and the bone marrow aspirate revealed 98% lymphoblasts (10) . In the second case, FDG PET/CT was performed to detect and evaluate an inflammatory focus in a patient with FUO. Diffuse homogeneous FDG uptake was observed in the bone marrow without splenomegaly. The final diagnosis was ALL (11) .
In recent years, PET/CT has become a critical diagnostic tool in patients with FUO as a last resort procedure (12) . This modality has made a significant contribution to the differential diagnosis of FUO. Keidar et al. reported that PET/ CT identified the underlying cause of fever in 22 (46%) of 48 patients and contributed to the diagnosis in 90% of the patients (13) . Bleeker-Rovers et al. evaluated the distribution of diagnosis among patients with FUO based on published cases. They reported that the percentage of undiagnosed patients with FUO has increased from 9% to 51%, albeit in association with the development of medical diagnostic procedures, in the last fifty years (14) .
In conclusion, if PET/CT reveals a diffuse high FDG uptake in the bone marrow on an evaluation of FUO while the examination of the peripheral blood shows no remarkable abnormalities, then a bone marrow biopsy should be considered in order to make a diagnosis of hematological malignancy.
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